Form 4: Precision BioSciences Director Receives RSU Grant

Director Melinda Brown was granted 20,979 restricted stock units by Precision BioSciences, Inc.

Summary

• Director Melinda Brown received a grant of 20,979 restricted stock units (RSUs) on June 3, 2026.
• Each RSU represents a contingent right to receive one share of Precision BioSciences common stock.
• The grant has a zero-dollar exercise price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon vesting.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The RSUs vest on the earlier of June 3, 2027, or the day prior to the next annual meeting of stockholders, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The vesting schedule aligns with typical one-year director equity retention cycles.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon the eventual conversion of RSUs to common stock.

Next Steps

• Vesting of the RSU grant on June 3, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

Precision BioSciences, DTIL, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation